Dr. Galsky explains the biomarker challenge with adjuvant immunotherapy in urothelial cancer

In an interview during the SUO 23rd Annual Meeting, Matthew Galsky, MD, described the biomarker challenge facing researchers as they continue to explore the use of immune checkpoint inhibitors in the adjuvant setting for patients with high-risk urothelial cancer.

Galsky is a professor of Medicine and director of Genitourinary Medical Oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute.